Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Feb;22(1):145-155.
doi: 10.1007/s10456-018-9646-1. Epub 2018 Sep 6.

Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia

Marie E Faughnan  1   2 , James R Gossage  3 , Murali M Chakinala  4 , S Paul Oh  5 , Raj Kasthuri  6 , Christopher C W Hughes  7 , Justin P McWilliams  8 , Joseph G Parambil  9 , Nicholas Vozoris  10   11 , Jill Donaldson  12 , Gitanjali Paul  12 , Pamela Berry  13 , Dennis L Sprecher  12
Affiliations
Clinical Trial

Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia

Marie E Faughnan et al. Angiogenesis. 2019 Feb.

Abstract

Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic telangiectasia (HHT). We report a prospective, multi-center, open-label, dose-escalating study [50 mg, 100 mg, 200 mg, and 400 mg], designed as a proof-of-concept study to demonstrate efficacy of pazopanib on HHT-related bleeding, and to measure safety. Patients, recruited at 5 HHT Centers, required ≥ 2 Curacao criteria AND [anemia OR severe epistaxis with iron deficiency]. Co-primary outcomes, hemoglobin (Hgb) and epistaxis severity, were measured during and after treatment, and compared to baseline. Safety monitoring occurred every 1.5 weeks. Seven patients were treated with 50 mg pazopanib daily. Six/seven showed at least 50% decrease in epistaxis duration relative to baseline at some point during study; 3 showed at least 50% decrease in duration during Weeks 11 and 12. Six patients showed a decrease in ESS of > 0.71 (MID) relative to baseline at some point during study; 3/6 showed a sustained improvement. Four patients showed > 2 gm improvement in Hgb relative to baseline at one or more points during study. Health-related QOL scores improved on all SF-36 domains at Week 6 and/or Week 12, except general health (unchanged). There were 19 adverse events (AE) including one severe AE (elevated LFTs, withdrawn from dosing at 43 days); with no serious AE. In conclusion, we observed an improvement in Hgb and/or epistaxis in all treated patients. This occurred at a dose much lower than typically used for oncologic indications, with no serious AE. Further studies of pazopanib efficacy are warranted.

Keywords: Anemia; Epistaxis; Hereditary; Telangiectasia; Tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

MF reports grants from GSK, during the conduct of the study; personal fees from HHT Foundation International (Cure HHT), grants from NIH-NINDS-NCATS, grants from NIH-NHLBI, grants from US Department of Defense, outside the submitted work; MCM reports grants from GSK, during the conduct of the study; grants from HHT Foundation International, personal fees from Express Scripts International, outside the submitted work. JD is a GSK employee and share holder. GP reports other from Novartis, during the conduct of the study; other from GSK, outside the submitted work; PB reports other from GSK, other from Janssen Global Services, outside the submitted work. DLS reports other from GlaxoSmithKline, outside the submitted work; and I have worked with the HHT patient advocacy group for many years, but receive no monies related to that activity. However, this has motivated my interest in pursuing this work; JG, SPO, RK, CCWH, JM, JGP, NV have nothing to disclose.

Figures

Fig. 1
Fig. 1
HB (gm/dL) and duration of epistaxis (min/2 weeks) for each patient, Reported at baseline, during therapy, and post-treatment follow-up
Fig. 1
Fig. 1
HB (gm/dL) and duration of epistaxis (min/2 weeks) for each patient, Reported at baseline, during therapy, and post-treatment follow-up
Fig. 2
Fig. 2
Epistaxis severity score (ESS) for each patient, with group means, reported at baseline, after 6 and 12 weeks of therapy, and at follow-up. The dashed line represents the time period after drug discontinuation in Patient 5
See this image and copyright information in PMC

References

    1. Donaldson JW, McKeever TM, Hall IP, Hubbard RB, Fogarty AW. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study. Thorax. 2014;69(2):161–167. doi: 10.1136/thoraxjnl-2013-203720. - DOI - PubMed
    1. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345–351. doi: 10.1038/ng1294-345. - DOI - PubMed
    1. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13(2):189–195. doi: 10.1038/ng0696-189. - DOI - PubMed
    1. Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4) Lancet. 2004;363(9412):852–859. doi: 10.1016/S0140-6736(04)15732-2. - DOI - PubMed
    1. Ingrosso M, Sabba C, Pisani A, Principi M, Gallitelli M, Cirulli A, et al. Evidence of small-bowel involvement in hereditary hemorrhagic telangiectasia: a capsule-endoscopic study. Endoscopy. 2004;36(12):1074–1079. doi: 10.1055/s-2004-826045. - DOI - PubMed

Publication types